ABSTRACT The ability of the Hi receptor antagonist clemastine to prevent exercise-induced asthma (EIA) has been studied in 10 adult asthmatic subjects. Exercise was performed for eight minutes on a cycle ergometer on two occasions on each of two days. The 
Although much has been learned about the mechanisms of asthma little is known of the immediate cause of increased airways obstruction which occurs in many asthmatic individuals after a brief period of exertion.
Recent work has related exercise-induced asthma (EIA) to hyperventilation and subsequent airway cooling, although it is not clear whether this would act primarily on vagal irritant receptors' or whether it might have a direct effect on mast cells leading to the release of active mediators such as histamine. 2 We have investigated the role of histamine by the use of a specific Hi receptor blocking agent, clemastine, having previously shown that this antihistamine, given by aerosol inhalation, is a bronchodilator and can inhibit histamine-induced bronchoconstriction.3 4 
Methods
Fifteen patients with stable bronchial asthma gave their informed consent to the study. All had pre-viously been shown to have exercise-induced asthma (fall in peak expiratory flow rate, PEFR, or forced expiratory volume in one second, FEV, of > 15% after exercise).
Patients performed two exercise tests separated by two hours on each of two study days. The initial test on each day was used to confirm that a similar degree of exercise asthma was present. If the fall in PEFR or FEV1 was <15% after the first test, the subject was asked to attend on another occasion, or was withdrawn from the study. If, in addition, at the second visit, the fall in PEFR or FEV1 differed by more than 15% from that at the first, then that individual's response to exercise was considered too variable and he was not included in the study.
Ten patients were considered to have reproducible EIA by the criteria outlined above, and their results form the basis of this report. Their mean age was 35 years (range 24-45 yr) and six were male. Nine patients had positive skin prick tests to two or more common allergens. No drugs were permitted within 12 More recently, attempts have been made to look for mediators directly in peripheral blood during attacks of EIA. Histamine is the first substance to be so investigated, since sensitive enzymatic or fluorimetric assays are now available, but the reported findings are conflicting."15-7 An approach which has so far received little attention is the use of specific mediator antagonists to block EIA.
The study we report here has shown that clemastine significantly reduced EIA in our group of 10 patients. Some improvement in EIA was seen in all subjects, as assessed by PEFR and FEV,, with the exception of the FEV, response of patient 6 . Marked protection (protection index >50%) was seen in five subjects using PEFR and six using FEV,. No subject had a protection index above 50% with saline according to PEFR measurements, while only one did so according to the FEV,. The placebo response in our study was therefore low, and this, together with the uniform effect of clemastine, was responsible for the highly significant result. The degree of protection afforded by clemastine for the whole group is moderate, being slightly lower than that reported for methyl xanthines and sodium cromoglycate, and much lower than that reported for salbutamol,9 10 but in the latter study, the protection index for placebo was higher than our own at 25%. We consider that the design of our trial has allowed genuine responses to be more clearly distinguished from placebo effects and the natural variation of EIA itself.
We think it unlikely that clemastine affected EIA in any way other than by blocking the action of histamine released during exericse. Although significant bronchodilatation was produced, this was of a much smaller order than we have found in patients recovering from acute severe asthma,-" and the improvement in lung function did not correlate individually with protection against EIA. Similarly, clemastine is unlikely to have blocked vagal reflex bronchoconstriction. Although many antihistamines possess anticholinergic activity.
clemastine has been shown to be ineffective in preventing methacholine-induced bronchoconstriction in doses similar to those used in the present study, and which were able to block the effects of inhaled histamine. 4 
